Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review].
Zhonghua Xue Ye Xue Za Zhi
October 2024
Department of Hematology, The Myeloma & Lymphoma Center, The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 200003, China.
Multiple myeloma (MM) is a malignant plasma cell disease that currently cannot be cured. Several new drugs have continuously been introduced in the recent years. New drugs targeting B-cell maturation antigen (BCMA) have greatly improved the efficacy and prognosis of MM compared with traditional treatments.
View Article and Find Full Text PDFRe-irradiation for recurrent glioblastoma: a pattern of care analysis.
BMC Neurol
November 2024
Radiation Oncology Center Mittelland, Kantonsspital Aarau, Aarau, Switzerland.
Background: 90% of glioblastomas (GBM) relapse within two years of diagnosis. In contrast to the initial setting, there is no standard management for recurrent disease and options include hypofractionated stereotactic re-irradiation (re-mHSRT). The aims of this study were to investigate re-mHSRT practice in Swiss neuro-oncology centres.
View Article and Find Full Text PDFEfficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab.
Adv Ther
November 2024
Department of Dermatology, Northwest Hospital, The Second Hospital Affiliated to Xi'an Jiaotong University, 157 Xiwu Road, Xi'an, 710004, China.
Introduction: In China, approximately 2.3 million people have psoriasis. Continuous treatment is recommended for moderate-to-severe psoriasis.
View Article and Find Full Text PDFRadiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation.
Cancer Radiother
November 2024
Institut Curie, université PSL, université Paris Saclay, Inserm Lito U1288, Orsay, France.
Purpose: This review systematically investigates the role of radiomics in radiotherapy, with a particular emphasis on the use of quantitative imaging biomarkers for predicting clinical outcomes, assessing toxicity, and optimizing treatment planning. While the review encompasses various applications of radiomics in radiotherapy, it particularly highlights its potential for guiding reirradiation of recurrent cancers.
Methods: A systematic review was conducted based on a Medline search with the search engine PubMed using the keywords "radiomics or radiomic" and "radiotherapy or reirradiation".
Overview of treatment plan quality in a high dose rate prostate brachytherapy workflow.
Brachytherapy
November 2024
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.
Purpose: High dose rate brachytherapy (HDR-BT) has been shown to be an effective treatment for prostate cancer, with treatment plan quality dependent on a number of factors. In this work, we report on the overall performance of our ultrasound (US)-based workflow and the impact of several treatment-specific variables.
Methods And Materials: Patients who underwent HDR-BT (boost, monotherapy, and retreatment) using Varian Bravos/US from 2021 to 2023 were sampled for this study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!